These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. HIV/AIDS: a minority health issue. Cargill VA; Stone VE Med Clin North Am; 2005 Jul; 89(4):895-912. PubMed ID: 15925655 [TBL] [Abstract][Full Text] [Related]
5. New studies highlight racial disparity, treatment access among HIV patients. Differences chiefly due to economic disparity. AIDS Alert; 2002 Nov; 17(11):133, 135-6. PubMed ID: 12412562 [TBL] [Abstract][Full Text] [Related]
6. Incremental drug treatment cost in HIV-positive patients in industry-sponsored clinical trials. Perrín RS; López FJ Ann Pharmacother; 2008 Nov; 42(11):1586-91. PubMed ID: 18780807 [TBL] [Abstract][Full Text] [Related]
7. Adherence strategies. Religion is important difference among HIV-infected Southern minority population. Adherence barriers largely are the same as the coasts. AIDS Alert; 2008 May; 23(5):56-7. PubMed ID: 18637260 [No Abstract] [Full Text] [Related]
8. Including marginalized populations in HIV clinical trials: a new role for nurse-researchers. Cohn EG Policy Polit Nurs Pract; 2007 Nov; 8(4):271-5. PubMed ID: 18337433 [TBL] [Abstract][Full Text] [Related]
9. Impact of resistance to antiretroviral therapy in the minority community. Rodriguez AE; Campo RE; Gathe JC; Kwakwa HA AIDS Read; 2004 Oct; 14(10 Suppl):S9-11. PubMed ID: 15497217 [TBL] [Abstract][Full Text] [Related]
11. HIV pill reminder device shows some adherence improvement. Technology now switched to cell phone. AIDS Alert; 2005 Dec; 20(12):139-40. PubMed ID: 16397940 [TBL] [Abstract][Full Text] [Related]
12. Multiple barriers prevent minorities' early treatment. AIDS stigma, lack of transportation top list. AIDS Alert; 2003 Nov; 18(11):137-8, 143. PubMed ID: 14674363 [TBL] [Abstract][Full Text] [Related]
13. Impact of current treatment guidelines on minority patients with HIV infection. Stone V; Virgil LA AIDS Read; 2004 Oct; 14(10 Suppl):S5-8. PubMed ID: 15497216 [TBL] [Abstract][Full Text] [Related]
14. Is it time to rethink the expanded-access programs for HIV infection? Amorosa V; Tebas P J Infect Dis; 2007 Oct; 196(7):974-7. PubMed ID: 17763316 [TBL] [Abstract][Full Text] [Related]
15. Clinical trials: making them work for you. Biel-Cunningham S Surviv News (Atlanta Ga); 2004; 15(1):8. PubMed ID: 15032143 [No Abstract] [Full Text] [Related]
16. Activism. Minority groups rise to meet needs of communities. AIDS Policy Law; 2003 Sep; 18(17):2. PubMed ID: 14626955 [No Abstract] [Full Text] [Related]
17. Research as a path to wide-scale implementation of antiretroviral therapy in Africa. Sanne I; van der Horst C J HIV Ther; 2004 Sep; 9(3):65-8. PubMed ID: 15534564 [TBL] [Abstract][Full Text] [Related]
18. The "seeded" focus group: a strategy to recruit HIV+ community members into treatment research. Busza J; Zaba B; Urassa M Sex Transm Infect; 2009 Jun; 85(3):212-5. PubMed ID: 18684857 [TBL] [Abstract][Full Text] [Related]
19. Tribulations and trials in HIV disease, Part I. Boyle BA AIDS Read; 2006 May; 16(5):240-4. PubMed ID: 16764065 [No Abstract] [Full Text] [Related]
20. Medicare D has big impact on HIV treatment interruptions. Decreased access to meds, six-fold increase in interruptions. AIDS Alert; 2008 Nov; 23(11):121-3. PubMed ID: 19043865 [No Abstract] [Full Text] [Related] [Next] [New Search]